F
Frédéric Commo
Researcher at Institut Gustave Roussy
Publications - 56
Citations - 3601
Frédéric Commo is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 30, co-authored 56 publications receiving 3269 citations. Previous affiliations of Frédéric Commo include French Institute of Health and Medical Research & Sage Bionetworks.
Papers
More filters
Journal ArticleDOI
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
Fabrice Andre,Fabrice Andre,Thomas Bachelot,Frédéric Commo,Mario Campone,Monica Arnedos,Véronique Diéras,Magali Lacroix-Triki,Ludovic Lacroix,Pascale Cohen,David Gentien,José Adélaïde,Florence Dalenc,Anthony Gonçalves,Christelle Levy,Jean-Marc Ferrero,Jacques Bonneterre,Claudia Lefeuvre,Marta Jimenez,Thomas Filleron,Hervé Bonnefoi +20 more
TL;DR: Personalisation of medicine for metastatic breast cancer is feasible, including for rare genomic alterations, according to a multicentre molecular screening study conducted in France.
Journal ArticleDOI
ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer
Luc Friboulet,Ken A. Olaussen,Ken A. Olaussen,Jean Pierre Pignon,Frances A. Shepherd,Ming-Sound Tsao,Stephen L. Graziano,Robert A. Kratzke,Jean-Yves Douillard,Lesley Seymour,Robert Pirker,Martin Filipits,Fabrice Andre,Fabrice Andre,Eric Solary,Eric Solary,Florence Ponsonnailles,Florence Ponsonnailles,Angélique Robin,Angélique Robin,Annabelle Stoclin,Annabelle Stoclin,Nicolas Dorvault,Nicolas Dorvault,Frédéric Commo,Frédéric Commo,Julien Adam,Julien Adam,Elsa Vanhecke,Elsa Vanhecke,Patrick Saulnier,Jürgen Thomale,Thierry Le Chevalier,Thierry Le Chevalier,Ariane Dunant,Vanessa Rousseau,Gwénaël Le Teuff,Elisabeth Brambilla,Jean-Charles Soria,Jean-Charles Soria +39 more
TL;DR: It was found that none of the 16 antibodies could distinguish among the four ERCC1 protein isoforms, whereas only one isoform produced a protein that had full capacities for nucleotide excision repair and cisplatin resistance.
Journal ArticleDOI
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Nicolas F. Delahaye,Sylvie Rusakiewicz,Sylvie Rusakiewicz,Isabelle Martins,Cédric Ménard,Cédric Ménard,Stephan Roux,Stephan Roux,Luc Lyonnet,Pascale Paul,Matthieu Sarabi,Matthieu Sarabi,Nathalie Chaput,Nathalie Chaput,Michaela Semeraro,Michaela Semeraro,Véronique Minard-Colin,Véronique Minard-Colin,Vichnou Poirier-Colame,Kariman Chaba,Kariman Chaba,Caroline Flament,Caroline Flament,Véronique Baud,Véronique Baud,Véronique Baud,Hélène Authier,Hélène Authier,Hélène Authier,Saadia Kerdine-Römer,Marc Pallardy,Isabelle Cremer,Isabelle Cremer,Laetitia Peaudecerf,Benedita Rocha,Dominique Valteau-Couanet,Dominique Valteau-Couanet,Javier Celis Gutierrez,Jacques A. Nunès,Frédéric Commo,Frédéric Commo,Sylvie Bonvalot,Nicolas Ibrahim,Philippe Terrier,Paule Opolon,Paule Opolon,Cristina Bottino,Cristina Bottino,Alessandro Moretta,Jan Tavernier,Pascal Rihet,Jean Michel Coindre,Jean-Yves Blay,Nicolas Isambert,Jean Franãois Emile,Eric Vivier,A. Lecesne,Guido Kroemer,Laurence Zitvogel +58 more
TL;DR: The genetically determined NKp30 status predicts the clinical outcomes of individuals with GIST independently from KIT mutation, and predominant expression of the immunosuppressiveNKp30c isoform was associated with reduced survival of subjects.
Journal ArticleDOI
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Celine Lefebvre,Thomas Bachelot,Thomas Filleron,Marion Pedrero,Mario Campone,Jean-Charles Soria,Christophe Massard,Christelle Levy,Monica Arnedos,Magali Lacroix-Triki,Julie Garrabey,Yannick Boursin,Marc Deloger,Yu Fu,Frédéric Commo,Véronique Scott,Ludovic Lacroix,Maria Vittoria Dieci,Maud Kamal,Véronique Diéras,Anthony Gonçalves,Jean-Marc Ferrerro,Gilles Romieu,Laurence Vanlemmens,Marie-Ange Mouret Reynier,J C Théry,Fanny Le Du,Séverine Guiu,Florence Dalenc,Gilles Clapisson,Hervé Bonnefoi,Marta Jimenez,Christophe Le Tourneau,Christophe Le Tourneau,Fabrice Andre,Fabrice Andre +35 more
TL;DR: This study revealed genomic alterations and mutational signatures involved in the resistance to therapies, including actionable mutations, in HR+/HER2− metastatic tumors as compared to primary TCGA samples.
Journal ArticleDOI
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors
Sylvie Rusakiewicz,Michaela Semeraro,Matthieu Sarabi,Mélanie Desbois,Clara Locher,Rosa Mendez,Nadege Vimond,Ángel Concha,Federico Garrido,Nicolas Isambert,Loic Chaigneau,Valérie Le Brun-Ly,Patrice Dubreuil,Isabelle Cremer,Anne Caignard,Vichnou Poirier-Colame,Kariman Chaba,Caroline Flament,Niels Halama,Dirk Jäger,Alexander M.M. Eggermont,Sylvie Bonvalot,Frédéric Commo,Philippe Terrier,Paule Opolon,Jean-François Emile,Jean-Michel Coindre,Guido Kroemer,Nathalie Chaput,Axel Le Cesne,Jean-Yves Blay,Laurence Zitvogel +31 more
TL;DR: It is found that CD3(+) TIL were highly activated in GIST and were especially enriched in areas of the tumor that conserve class I MHC expression despite imatinib mesylate treatment, which encourages the prospective validation of immune biomarkers for optimal risk stratification of patients with GIST.